SL1716 / SenlangBio - LARVOL DELTA

Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients (ASH 2025) - "Among treatment-refractory cases, 3 had prior CAR-T exposure,including 1 case of CD19/CD22 CAR-T and 2 case of CD19 CAR-T therapy, all with subsequent relapse.Following lymphodepletion, all patients received SL1716 (CD19/CD20 bispecific CAR-T) at 4×106 cells/kg,with 100% manufacturing success rate. SL1716, a nanobody-based CD19/CD20 bispecific CAR-T cell therapy, demonstrates afavorable safety profile and durable clinical efficacy in patients with r/r NHL. These promising resultssupport its potential as an effective treatment option for this high-risk patient population."

Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • CD20 • CD22

Big Announcement | Senlang Biotechnology’s 6 Cutting-Edge Achievements to be Showcased at ASH2025 [Google translation] (Senlang Biotech Press Release) - "The company will officially release six of its latest clinical research findings during the conference, including its core products: CD7-targeted SENL101, CD19/BCMA dual-targeted SL1703, CD19/CD20 dual-targeted SL1716, and BCMA/GPRC5D dual-targeted SL0439."

Clinical data • Multiple Myeloma • Non-Hodgkin’s Lymphoma